TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00343460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APF530
Description: Given subcutanously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APF530
Description: Given subcutanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given IV and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV and orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given subcutanously or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given subcutanously or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given subcutanously or IV
Study: NCT03475147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eyeFusion
Description: Smartphone app based flicker fusion test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eyeFusion
Description: Smartphone app based flicker fusion test.
Study: NCT03637738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RIOP-Intrabeam® system
Description: The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery +RTE
Description: Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
Study: NCT02769585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: Self-hypnosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDE training
Description: standard CDE training for an obese diabetic
Study: NCT02362282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm training
Description: Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
Study: NCT03702153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polypropylene mesh

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polypropylene mesh
Study: NCT06286488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip
Description: Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip
Description: Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
Study: NCT03071107

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-disciplinary intervention
Description: Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
Study: NCT01318460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan infusion
Description: Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Twenty-four hour administration of placebo
Study: NCT04085289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00646880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propiverine
Description: Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine PR
Description: Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
Study: NCT03292796

Intervention type: DRUG
Group type: OTHER
Intervention: Prostaglandins

Intervention type: DRUG
Group type: OTHER
Intervention: Prostaglandins
Study: NCT01035801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-105
Description: Prandial Oral Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Injection
Description: Insulin Lispro Injection
Study: NCT04198714

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pudendal block
Description: Administration of a pudendal block at the conclusion of vaginal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal block
Description: Administration of a pudendal block at the conclusion of vaginal surgery.
Study: NCT00328107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, recombinant Hemagglutinin
Description: 0.5mL dose for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, recombinant Hemagglutinin
Description: 0.5mL dose for IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine, recombinant Hemagglutinin
Description: 0.5mL dose for IM injection
Study: NCT04320316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crysvita (burosumab-twza) Treatment
Description: KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
Study: NCT03332706

Intervention type: OTHER
Intervention: observation
Description: after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy

Intervention type: OTHER
Intervention: observation
Description: after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
Study: NCT02660372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imonogas
Description: Simethicone 120 mg in gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Espumisan
Description: Simethicone 40 mg in gel capsules
Study: NCT02037399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous dexamethasone
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous normal saline
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Study: NCT02454517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Undergo DPP lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo DPP lifestyle intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive oral and written guidelines and meet with dietician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01655732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
Study: NCT04560699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic treatment and medical care
Description: Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical care
Description: medical care three times during the study period; baseline, week 13 and week 26
Study: NCT01630876

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vitrectomy only group
Description: The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined therapy group
Description: The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
Study: NCT03755349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of burr-hole covers
Description: Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No placement of burr-hole covers
Description: In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
Study: NCT01967329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Triple
Description: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple
Description: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple
Description: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple
Description: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Study: NCT01976091

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9004
Description: Isolated Limb Infusion (ILI)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9004
Description: Isolated Limb Infusion (ILI)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9004
Description: Isolated Limb Infusion (ILI)
Study: NCT03042819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
Study: NCT03967444

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic acid
Description: Injectable gel for lip augmentation

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic acid
Description: Injectable gel. Lip Augmentation and other wrinkles/folds
Study: NCT02359097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo MRI including DSC or DCE-CBV mapping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI including SS-CBV
Study: NCT01605799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IOK Killing Treatment
Description: The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IOK Killing Treatment
Description: The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list control group
Description: Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
Study: NCT04129996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab in combination with nab-paclitaxel and famitinib
Description: camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
Study: NCT06369727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: Topcal formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MOB015B vehicle
Description: Topcal formulation

Intervention type: DRUG
Group type: OTHER
Intervention: Negative irritant solution of 0.9% saline
Description: Negative control
Study: NCT01902095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tooth powder
Description: Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth paste (control)
Description: Active Comparator
Study: NCT01641185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation with protons or carbon ions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation with protons or carbon ions
Study: NCT03811704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical navigation system
Description: We will use this navigation system to guide de liver resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
Study: NCT00558649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (FLUARIX®)
Description: Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (FLUARIX®)
Description: Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine (FLUARIX®)
Description: Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
Study: NCT00179192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure